| Autor: |
de Sousa Pinto M; Faculty of Pharmacy, Graduate Program in Health Assistance and Evaluation, Federal University of Goiás, Goiânia, Brazil.; Institute of Health Sciences, Alfredo Nasser University Center, Goiânia, Goiás, Brazil., Fontoura LGO; Institute of Health Sciences, Alfredo Nasser University Center, Goiânia, Goiás, Brazil., da Rosa Borges I; Institute of Health Sciences, Alfredo Nasser University Center, Goiânia, Goiás, Brazil., Vieira de Melo Bisneto A; Institute of Biological Sciences, Department of Genetics, Laboratory of Radiobiology and Mutagenesis, Federal University of Goiás, Goiânia, Brazil., Rosa de Oliveira G; Institute of Health Sciences, Alfredo Nasser University Center, Goiânia, Goiás, Brazil., Carneiro LC; Department of Biotechnology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Goiás, Brazil., Chen Chen L; Institute of Biological Sciences, Department of Genetics, Laboratory of Radiobiology and Mutagenesis, Federal University of Goiás, Goiânia, Brazil., Vieira de Moraes Filho A; Faculty of Pharmacy, Graduate Program in Health Assistance and Evaluation, Federal University of Goiás, Goiânia, Brazil.; Institute of Health Sciences, Alfredo Nasser University Center, Goiânia, Goiás, Brazil. |
| Abstrakt: |
Although the last pandemic created an urgency for development of vaccines, there was a continuous and concerted effort to search for therapeutic medications among existing drugs with different indications. One of the medications of interest that underwent this change was infliximab (IFM). This drug is used as an anti-inflammatory, predominantly in patients with Crohn 's disease, colitis ulcerative, and rheumatoid arthritis. In addition to these patients, individuals infected with Coronavirus Disease (COVID-19) were administered this chimeric monoclonal antibody (IMF) to act as an immunomodulator for patients in the absence of comprehensive research. Consequently, the present study aimed to examine the genotoxic effects attributed to IFM treatment employing different assays in vivo using mouse Mus musculus . Therefore, IFM was found to induce genotoxic effects as evidenced by the comet assay but did not demonstrate genotoxic potential utilizing mouse bone marrow MN test. The results of evaluating the expression of the P53 and BCL-2 genes using RT-qPCR showed stimulation of expression of these genes at 24 hr followed by a decline at 48 hr. Although the comet assay provided positive results, it is noteworthy that based upon negative findings in the micronucleus test, the data did not demonstrate significant changes in the genetic material that might affect the therapeutic use of IFM. The stimulation of expression of P53 and BCL-2 genes at 24 hr followed by a decline at 48 hr suggest a transient, if any, effect on genetic material. However, there is still a need for more research to more comprehensively understand the genotoxic profile of this medication. |
